Renal cell carcinoma and interleukin-2: what are the endpoints?
Figlin
R A
RA
D002292:Carcinoma, Renal Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D016896:Treatment Outcome
D007376:Interleukin-2